Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492044 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12391585 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL12339200 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23450964 | 0.74 | — | — | |
| SCHEMBL5217357 | 0.74 | — | — | |
| SCHEMBL15387249 | 0.74 | — | — | |
| SCHEMBL14417056 | 0.74 | — | — | |
| SCHEMBL1052630 | 0.74 | MAPK1 (0.33) | ALDH1A1 | |
| SCHEMBL16772325 | 0.74 | — | — | |
| SCHEMBL5851756 | 0.73 | CYP2C9 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943975-B | Pyrazole amide compound containing silicon atoms, preparation method and application thereof, and bactericide | 华中师范大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-110194744-B | Compound for inhibiting beta-amyloid protein generation and preparation method and application thereof | 云南大学 | 2022-11-11 | — | — | CN | disclosed |
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. | 2016-05-19 | — | — | US | disclosed |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. | 2013-05-30 | — | — | US | disclosed |
| WO-2011140338-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079231-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | GATEKEEPER PHARMACEUTICAL, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| EP-0961786-B1 | MOLECULAR WEIGHT CONTROLLED POLYMERS BY PHOTOPOLYMERIZATION | DU PONT (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6316519-B1 | CONTACTING MONOETHYLENICALLY UNSATURATED MONOMER WITH PHOTOINITIATOR; CONTACTING WITH ACTINIC RADIATION IN A PHOTOREACTOR, AND FORMING A LINEAR POLYMER OF CONTROLLED MOLECULAR WEIGHT | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-0961786-A1 | MOLECULAR WEIGHT CONTROLLED POLYMERS BY PHOTOPOLYMERIZATION | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998037104-A1 | MOLECULAR WEIGHT CONTROLLED POLYMERS BY PHOTOPOLYMERIZATION | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
| US-4272530-A | ESTROGENIC ACTIVITY | ROUSSEL UCLAF (FR) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ALDH1A1 3511/4885 |
| US-20160137610-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | ALDH1A1 2351/4885 |
| US-20130137709-A1 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | EGFR, ERBB2, BRCA1 | ALDH1A1 2351/4885 |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | ALDH1A1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.